vTv Therapeutics (VTVT)
NASDAQ:VTVT
Want to see VTVT full AI Analyst Report?
Top Page
vTv Therapeutics
(NASDAQ:VTVT)
Select Model
Select Model
Rating:56Neutral
Price Target:
$40.00
▲(4.93% Upside)
Action:Reiterated
Date:05/15/26
The score is held back primarily by weak underlying fundamentals (ongoing operating losses and negative free cash flow) despite a cleaner balance sheet. Technicals are moderately supportive with price above key moving averages, while valuation looks inexpensive on P/E. Corporate updates add a positive catalyst and runway narrative, but execution and cash burn remain central risks.
Positive Factors
Low leverage / stronger capitalization
Minimal debt and materially improved equity versus prior years reduce solvency and refinancing risk. This stronger capitalization lengthens the company’s ability to fund clinical programs, supports partner discussions, and provides strategic optionality during multi-year Phase 3 execution.
Negative Factors
Persistent negative cash flow
Consistent negative operating and free cash flow (TTM FCF ~ -$10.4M) signals ongoing burn to fund R&D. Continued cash deficits constrain reinvestment, increase dependence on external capital, and limit ability to scale commercialization without partnering or new financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / stronger capitalization
Minimal debt and materially improved equity versus prior years reduce solvency and refinancing risk. This stronger capitalization lengthens the company’s ability to fund clinical programs, supports partner discussions, and provides strategic optionality during multi-year Phase 3 execution.
Read all positive factors
vTv Therapeutics (VTVT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$139.79M
Dividend YieldN/A
Average Volume (3M)5.07K
Price to Earnings (P/E)5.1
Beta (1Y)0.66
Revenue Growth216600.00%
EPS Growth79.14%
CountryUS
Employees23
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.29
Shares Outstanding3,938,654
10 Day Avg. Volume5,801
30 Day Avg. Volume5,072
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)5.23
Price to Sales (P/S)0.00
P/FCF Ratio-13.34
Enterprise Value/Market Cap-0.02
Enterprise Value/Revenue-0.06
Enterprise Value/Gross Profit-0.06
Enterprise Value/Ebitda1.19
Forecast
1Y Price Target
$53.00Price Target Upside39.03% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-2.57
Revenue Forecast (FY)$13.33M
vTv Therapeutics Business Overview & Revenue Model
Company Description
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase...
How the Company Makes Money
As a clinical-stage biopharmaceutical company, vTv Therapeutics has historically not generated meaningful recurring revenue from product sales because it does not have widely disclosed commercial products. Its cash inflows have primarily been asso...
vTv Therapeutics Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 36.84M | 0.00 | 1.02M | 0.00 | 2.02M | 4.00M |
| Gross Profit | 36.84M | 0.00 | 1.02M | 0.00 | 2.02M | 4.00M |
| EBITDA | -1.93M | -31.06M | -22.52M | -25.86M | -24.77M | -17.52M |
| Net Income | 2.25M | -26.97M | -18.46M | -20.25M | -19.16M | -12.99M |
Balance Sheet | ||||||
| Total Assets | 98.81M | 89.90M | 38.27M | 11.02M | 33.24M | 25.47M |
| Cash, Cash Equivalents and Short-Term Investments | 98.09M | 88.93M | 36.75M | 9.45M | 12.13M | 13.41M |
| Total Debt | 0.00 | 0.00 | 169.00K | 529.00K | 716.00K | 932.00K |
| Total Liabilities | 8.85M | 25.46M | 23.96M | 29.57M | 27.40M | 10.25M |
| Stockholders Equity | 89.96M | 64.44M | 12.20M | -24.68M | -10.74M | -9.74M |
Cash Flow | ||||||
| Free Cash Flow | -10.41M | -25.25M | -25.31M | -19.08M | -15.27M | -19.31M |
| Operating Cash Flow | -10.41M | -25.25M | -25.31M | -19.08M | -15.25M | -19.31M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 4.40M | -21.00K | 0.00 |
| Financing Cash Flow | 77.44M | 77.44M | 52.61M | 12.00M | 13.98M | 26.98M |
vTv Therapeutics Technical Analysis
Positive
38.12
Price Trends
35.67
Positive
36.05
Positive
29.63
Positive
Market Momentum
-0.15
Negative
55.52
Neutral
70.50
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VTVT, the sentiment is Positive. The current price of 38.12 is above the 20-day moving average (MA) of 33.13, above the 50-day MA of 35.67, and above the 200-day MA of 29.63, indicating a bullish trend. The MACD of -0.15 indicates Negative momentum. The RSI at 55.52 is Neutral, neither overbought nor oversold. The STOCH value of 70.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VTVT.
vTv Therapeutics Risk Analysis
vTv Therapeutics disclosed 19 risk factors in its most recent earnings report. vTv Therapeutics reported the most risks in the "Production" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
vTv Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $139.79M | 5.10 | -74.07% | ― | 216600.00% | 79.14% | |
53 Neutral | $180.73M | -2.46 | -91.12% | ― | ― | ― | |
53 Neutral | $160.64M | -4.32 | -48.20% | ― | 7336.90% | 49.64% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $86.76M | -1.77 | 233.93% | ― | -61.71% | -11.47% | |
47 Neutral | $77.24M | -2.07 | -30.19% | ― | ― | 63.31% | |
44 Neutral | $73.07M | -0.97 | -59.06% | ― | ― | 49.00% |
* Healthcare Sector Average
VTVT
vTv Therapeutics
36.49
16.50
82.54%
ATHE
Alterity Therapeutics
4.27
0.26
6.48%
IFRX
InflaRx
2.37
0.68
40.24%
CLNN
Clene
6.38
3.88
155.20%
PLRX
Pliant Therapeutics
1.15
-0.18
-13.53%
ADAG
Adagene
3.40
1.74
104.82%
vTv Therapeutics Corporate Events
Private Placements and FinancingRegulatory Filings and Compliance
vTv Therapeutics Expands At-The-Market Share Program Capacity
Neutral
May 13, 2026
On May 13, 2026, vTv Therapeutics Inc. moved to expand its financial flexibility by filing a prospectus supplement with the SEC to increase the number of Class A common shares available under its previously announced at-the-market sales program. T...
Business Operations and StrategyFinancial Disclosures
vTv Therapeutics Highlights Cadisegliatin Phase 3 and Cash Runway
Positive
Mar 11, 2026
On March 10, 2026, vTv Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on diabetes and other metabolic and immune-related diseases, posted an updated corporate slide presentation highlighting its late-stage pipeline and fina...
Business Operations and StrategyFinancial DisclosuresProduct-Related Announcements
vTv Therapeutics Highlights Cadisegliatin Progress and Financial Strength
Positive
Feb 26, 2026
On February 26, 2026, vTv Therapeutics posted an updated corporate slide presentation outlining the progress of cadisegliatin, its late-stage oral adjunctive therapy candidate for type 1 diabetes, and its broader pipeline. The company highlighted ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.